Articles tagged with Lung Cancer
Researchers at Case Western Reserve University have developed a novel computerized approach to detect lung cancer using routine CAT scans. The method analyzes patterns of heterogeneity within and outside the tumor, distinguishing benign from malignant nodules with high accuracy.
A new study published in Molecular Therapy Oncolytics found that combining chemotherapy with CRISPR-Cas9 can stop tumor growth and reduce existing tumor volume in both tissue culture and mouse models. The CRISPR application disables the NRF2 gene, which helps lung cancer tumors develop resistance to chemotherapies.
A new study published in BMJ found that primary care doctors need to work six more hours a day to provide recommended preventive care, including colonoscopy and lung cancer screening. The simulation model also reveals that this would lead to 17 out of every 100 doctors taking early retirement each year.
The MYSTIC trial found that first line immunotherapy combination with durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer. However, a subgroup of patients with high tumour mutational burden showed improved overall survival with the combination treatment.
A study of over 280,000 people found a significant association between work stress and increased risk of colorectal and esophagus cancers. However, no link was observed for prostate, breast, or ovarian cancers, with the relationship varying by region.
Researchers identified a key enzyme linked to therapy resistance in EGFR-mutant non-small cell lung cancer. The study found that inhibiting this enzyme can lead to tumor regression and improved treatment outcomes.
Researchers predict a decline in cancer death rates in Australasian countries and Russia in 2018. However, the largest number of deaths are predicted for Russia, mainly due to high rates among men who still smoke. The study highlights the need for urgent measures on tobacco control in Russia.
A new epigenetic therapy targeting enzyme G9a boosts cancer stem cells that drive adenocarcinoma in mice, but also identifies a strategy reducing these cells. Researchers now explore demethylase inhibitors as potential therapeutic drugs to curb lung cancer progression.
The combination therapy of NIR178 and spartalizumab has shown activity in non-small cell lung cancer patients, with two complete responses and 14 patients experiencing stable disease. The treatment was well-tolerated, with most side effects being mild to moderate.
Scientists at UCLA have identified sodium glucose transporter 2 (SGLT2) as a key mechanism in lung cancer cell growth, which could lead to earlier diagnosis and treatment. The study found that SGLT2 is predominantly used by lung cancer cells to transport glucose, even in pre-malignant lesions.
Researchers at the Salk Institute found that late-stage cancers trigger AMPK's cellular recycling signal to cannibalize cell pieces, supplying large lung tumors with nutrients. Blocking AMPK in some conditions may stop advanced tumor growth.
Researchers have developed a new strategy against HER2-driven lung cancers using tarloxotinib, a potent HER2/EGFR inhibitor that is more active in low-oxygen conditions than existing therapies. This innovative approach has shown significant promise in treating patients with HER2 lung cancer.
Research suggests excessive sitting increases risk of premature death and chronic diseases by 10-20%, but this risk pales in comparison to smoking's significant harm. Smoking carries a substantially higher risk of cancer, cardiovascular disease, and lung cancer compared to sitting.
Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
The IASLC affirms the strength of evidence supporting lung cancer screening, reducing mortality by 26-61% in high-risk populations. The organization recommends implementing global lung cancer screening programs, incorporating multidisciplinary teams and best-practice smoking cessation.
A study found that angiotensin converting enzyme inhibitor (ACEI) drugs increase the risk of lung cancer by 14% compared to angiotensin receptor blockers (ARBs). The risk is highest among patients using ACEIs for over five years, particularly those who use them for more than 10 years.
A randomized study shows erlotinib improves progression-free survival and tumor response rate compared to gemcitabine plus cisplatin in stage IIIA-N2 EGFR-mutated NSCLC. Median progression-free survival was significantly longer with erlotinib at 21·5 months versus 11.9 months with chemotherapy.
Studies show that exercise can significantly reduce fatigue and improve well-being in patients with advanced lung cancer, improving symptom scores by approximately 10% during chemotherapy. Gentle aerobic exercise and strength training are recommended as part of treating the disease.
Researchers at Huntsman Cancer Institute discovered that different types of lung tumors recruit distinct immune cells, which can help or hinder tumor growth. The study found that high levels of neutrophils are associated with a bad response to immunotherapy, suggesting them as a potential target for new treatments.
Researchers found that a blood test identified significantly more treatable mutations in non-small cell lung cancer (NSCLC) than a tissue biopsy alone. Patients with actionable mutations detected by the liquid biopsy responded favorably to targeted therapies, achieving high clinical response rates.
A recent study published in Cancer Prevention Research reveals that California's long-term tobacco control efforts have led to a 28% decrease in lung cancer deaths compared to the rest of the country. The state's approach has been particularly effective in discouraging young people from starting to smoke, with a 39% lower initiation ra...
A new technology called EFIRM has been developed to detect two cancer-linked mutations in blood or saliva samples from patients with early-stage lung cancer. The platform shows promise in identifying stages 1 and 2 NSCLC when surgical resection is still possible, offering a potential cure.
Researchers found no clear evidence that statins benefit patients with non-Cardiovascular Disease (CVD) conditions, except for preventing deaths from kidney disease. Statins may also slow cancer progression, but further investigation is needed.
Researchers at UCLA will use a new liquid biopsy tool to test individuals at risk of lung cancer, with the goal of detecting the disease earlier. The technology aims to differentiate between cancerous and benign lung lesions, reducing unnecessary procedures and improving patient outcomes.
The report reveals a high burden of prostate and colorectal cancers among Hispanic men in Puerto Rico, contrasting with lower rates among non-Hispanic whites. The study emphasizes the need for culturally tailored strategies to address these disparities and promote healthy lifestyle behaviors.
A study found that despite a well-designed low-dose computed tomography (LDCT) screening program, only 77.6% of eligible veterans underwent annual repeat scans. This highlights the need for improved adherence to lung cancer screening to maximize mortality benefits and cost-efficacy.
Researchers found that more frequent surveillance imaging was not associated with improved overall survival for NSCLC patients. Annual surveillance is recommended as a standard practice, offering no additional benefits over six-monthly visits.
Scientists at UNIGE discovered that resveratrol, a molecule in grape skin and seeds, can prevent lung cancer in mice treated with a nasal formulation. The study showed a 45% decrease in tumor load and a higher concentration of resveratrol in the lungs after nasal administration.
Moffitt researchers used a new technique to identify a previously unknown mechanism of midostaurin in lung cancer. Combining functional proteomics with deep network analysis led to the discovery of TBK1, PDPK1, and AURKA as protein targets for midostaurin, resulting in a more effective combination therapy.
A new clinical trial has found that durvalumab improved progression-free survival by 17.2 months compared to placebo in patients with stage 3 non-small cell lung cancer. Overall survival rates also increased, with 66.3% of patients surviving at two years, compared to 55.6% on placebo.
The ALTA-1 trial found brigatinib to be a first-line treatment option for advanced ALK-positive non-small cell lung cancer, with a 51% reduction in progression or death risk compared to crizotinib. Patients treated with brigatinib also showed improved response rates and longer progression-free survival.
A study published in JAMA Oncology found that patients treated with more-invasive surgical techniques for early-stage lung cancer were more likely to become chronic opioid users. In contrast, those who underwent minimally invasive VATS surgery were less likely to fill opioid prescriptions after surgery and in the long term.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis
A recent SWOG study found that women diagnosed with non-small cell lung cancer (NSCLC) have a higher overall survival rate compared to men. The analysis revealed significant differences in survival rates among female and male patients, regardless of their smoking history or other factors.
Case Western Reserve University researchers have discovered a way to predict which lung cancer patients will benefit from chemotherapy based on the arrangement of immune cells. This information may aid in decision-making for routine tissue-slide images, potentially sparing patients from invasive treatments.
The ESMO Award 2018 is bestowed on Jean-Charles Soria, a pioneer in developing anti-cancer drugs, while Tony Mok receives the ESMO Lifetime Achievement Award for his practice-changing contribution to lung cancer. Pasi Jänne and Margaret Foti also receive awards for their translational research and mentorship efforts, respectively.
A study published in Radiology found that thermal ablation is a safe and effective treatment for early-stage non-small cell lung cancer, delivering comparable survival rates to stereotactic radiotherapy. The one-time treatment also offers direct access to the tumor, enabling biopsy samples and potentially lower costs.
A new study analyzed data from two UK and US centers to find that patients with advanced lung cancer often receive multiple medications that may not be beneficial. On average, these patients were prescribed 1.9-2.6 preventative medications at admission and discharge. The authors suggest developing an intervention to reduce inappropriat...
The human microbiome plays a significant role in cancer development and treatment, according to six original review articles in this special issue. The articles discuss the impact of probiotics, chemotherapy, and gut microbiota on cancer, as well as the use of microbial DNA sequencing techniques.
Researchers developed an AI system to detect tiny lung cancer tumors in CT scans, achieving 95% accuracy compared to human eyes at 65%. The system uses a connection-based approach similar to facial recognition software to identify patterns.
A study at Dartmouth has uncovered two significant pathogenic pathways contributing to the development of lung cancer. The research, led by Xuemie Ji, identified interaction pathways in the nervous system and cellular processes involved in nutrient transport and immune response.
A study by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center found that doctor-patient discussions about lung cancer screening are often brief and one-sided, failing to address potential harms. The conversation quality was rated as poor, with only a few minutes spent discussing the issue on average.
Researchers identify MUC5AC gene as a key player in KRAS-mutant non-small cell lung cancers, which are resistant to current treatments. Inhibiting this gene may lead to new therapeutic strategies against KRAS-driven lung cancer.
A large-scale patient population study reveals that palliative care is associated with a significantly reduced risk of suicide in veterans diagnosed with advanced stage lung cancer. The findings show that patients who received at least one palliative care visit had an 81% lower rate of suicidal death.
A CU Cancer Center study found that common laboratory tests used to determine ROS1 status in lung cancer have inherent limitations, leading to false-negative results. The study highlights the need for multiple testing methods and secondary analysis to confirm results, particularly for patients with suspicious symptoms or unusual profiles.
A study found that reducing NOVA1 gene activity inhibits telomerase, leading to shorter telomeres and reduced tumor growth in non-small cell lung cancer. The research provides a new approach to targeting cancer cells and may lead to more effective treatments for this prevalent form of age-related cancer.
The study found that individuals from underrepresented communities are more likely to have positive scans and diagnosed lung cancer cases, highlighting the need for more expansive, risk-based screening guidelines. The researchers suggest considering additional factors such as a history of chronic obstructive pulmonary disease and socio...
The global age-standardized lung cancer mortality rate among women is expected to rise by 43% from 2015 to 2030, while breast cancer mortality rates are projected to decrease by 9%. Lung cancer mortality rates will be highest in Europe and Oceania, with lower rates in America and Asia.
Researchers explored using saliva for early assessment of lung cancer and detection of stress hormones, enzyme levels, and developmental disease biomarkers. Saliva liquid biopsy shows promise in detecting circulating tumor DNA of lung cancer with high performance.
A recent study found that patients who smoke often misunderstand the benefits and limitations of lung cancer screenings. While LDCT scans can lower mortality rates, they do not reduce the risk of developing lung cancer. Quitting smoking remains the most effective way to prevent this disease.
Australian researchers found that follistatin, a naturally occurring hormone, can enhance the effectiveness of platinum-based chemotherapy and prevent kidney damage in lung cancer patients. The 'two birds, one stone' approach has shown promising results in mouse models.
A study published in the Journal of Thoracic Oncology found that active surveillance of lung subsolid nodules can reduce unnecessary surgery and overtreatment. Lung cancers arising from these nodules rarely led to death, suggesting they can be a biomarker for cancer risk.
Researchers found that omega-3 fatty acid metabolites, called endocannabinoids, can slow tumor growth and inhibit cancer cell migration in mice with osteosarcoma. These molecules were also shown to kill cancer cells, but not as effectively as other chemotherapeutic drugs.
A new biomarker blood test improves lung cancer risk assessment over existing guidelines, capturing risk for people who have ever smoked. The test achieved superior sensitivity and accuracy compared to guidelines for screening approved by the USPSTF for heavy smokers.
The RTOG 0618 trial found Stereotactic Body Radiation Therapy (SBRT) to achieve favorable primary tumor control and local control rates in operable early-stage lung cancer patients, with a low rate of toxicity. The results suggest that SBRT may be a viable alternative to surgery for this patient population.
The National Institute on Minority Health and Health Disparities (NIMHD) has selected recipients for its 2018 William G. Coleman Jr., Ph.D., Minority Health and Health Disparities Research Innovation Award, supporting innovative research in minority health disparities. The awarded projects focus on key determinants of health inequities...
The International Association for the Study of Lung Cancer (IASLC) has issued a statement paper on liquid biopsy for advanced non-small cell lung cancer, recommending its use for molecular analysis in guiding clinical management. The paper aims to provide general oncologists and clinicians with access to the latest information on liqui...
Researchers discovered that FDA-approved kinase inhibitors can curb lung tumor growth in mouse models, offering new therapeutic avenues for a hard-to-treat form of lung cancer. The findings highlight the potential of targeting ERBB receptor tyrosine kinases and EGFR signaling pathways to develop alternative treatment strategies.
The multicenter phase II trial assessed the safety and efficacy of lurbinectedin in different solid tumors, with an ORR of 39.3% seen in recurrent small-cell lung cancer patients. The median duration of response was 6.2 months and the median overall survival was 12 months.
Scientists are exploring ways to develop innovative therapies for treating non-small cell lung cancer (NSCLC) by understanding the role of deregulated protein kinases, or MAPKs. Elevated levels of these enzymes in NSCLC tissue have been linked to tumor progression and immune evasion.